JP2022527769A5 - - Google Patents
Info
- Publication number
- JP2022527769A5 JP2022527769A5 JP2021557367A JP2021557367A JP2022527769A5 JP 2022527769 A5 JP2022527769 A5 JP 2022527769A5 JP 2021557367 A JP2021557367 A JP 2021557367A JP 2021557367 A JP2021557367 A JP 2021557367A JP 2022527769 A5 JP2022527769 A5 JP 2022527769A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025028466A JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824876P | 2019-03-27 | 2019-03-27 | |
| US62/824,876 | 2019-03-27 | ||
| US201962934482P | 2019-11-12 | 2019-11-12 | |
| US62/934,482 | 2019-11-12 | ||
| PCT/US2020/024948 WO2020198466A1 (en) | 2019-03-27 | 2020-03-26 | Beta adrenergic agonist and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025028466A Division JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527769A JP2022527769A (ja) | 2022-06-06 |
| JPWO2020198466A5 JPWO2020198466A5 (https=) | 2023-02-03 |
| JP2022527769A5 true JP2022527769A5 (https=) | 2023-02-03 |
| JP7682097B2 JP7682097B2 (ja) | 2025-05-23 |
Family
ID=72607224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557367A Active JP7682097B2 (ja) | 2019-03-27 | 2020-03-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| JP2025028466A Pending JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025028466A Pending JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10947196B2 (https=) |
| EP (1) | EP3946329A4 (https=) |
| JP (2) | JP7682097B2 (https=) |
| KR (1) | KR102948270B1 (https=) |
| CN (1) | CN114007615A (https=) |
| AU (1) | AU2020248435B2 (https=) |
| BR (1) | BR112021018481A2 (https=) |
| CA (1) | CA3130291A1 (https=) |
| IL (1) | IL285759B2 (https=) |
| MX (1) | MX2021011728A (https=) |
| TW (1) | TWI886121B (https=) |
| WO (1) | WO2020198466A1 (https=) |
| ZA (1) | ZA202106625B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| EP4076422A4 (en) * | 2019-12-18 | 2024-01-24 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP7734700B2 (ja) * | 2020-06-04 | 2025-09-05 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニストの形態及び組成物 |
| EP4208159A4 (en) * | 2020-09-01 | 2024-09-25 | Curasen Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS |
| GB202015035D0 (en) | 2020-09-23 | 2020-11-04 | Atrogi Ab | New compounds and methods |
| GB202015044D0 (en) | 2020-09-23 | 2020-11-04 | Atrogi Ab | New compounds and methods |
| AU2021381373A1 (en) * | 2020-11-19 | 2023-06-29 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
| CN112592280B (zh) * | 2020-12-09 | 2023-05-23 | 青岛职业技术学院 | 一种消旋沙丁胺醇的制备方法 |
| GB202113588D0 (en) | 2021-09-23 | 2021-11-10 | Atrogi Ab | New compounds and methods |
| GB202113594D0 (en) | 2021-09-23 | 2021-11-10 | Atrogi Ab | New compounds and methods |
| MX2024003481A (es) * | 2021-09-23 | 2024-04-04 | Curasen Therapeutics Inc | Agonista beta adrenergico y metodos de uso del mismo. |
| US20230157974A1 (en) * | 2021-11-15 | 2023-05-25 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| GB2613616A (en) * | 2021-12-09 | 2023-06-14 | Atrogi Ab | New formulations |
| GB202204085D0 (en) | 2022-03-23 | 2022-05-04 | Atrogi Ab | New compounds and methods |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| WO2023225021A1 (en) * | 2022-05-17 | 2023-11-23 | Curasen Therapeutics, Inc. | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202304604D0 (en) | 2023-03-29 | 2023-05-10 | Atrogi Ab | New compounds and medical uses thereof |
| GB202304652D0 (en) | 2023-03-29 | 2023-05-10 | Atrogi Ab | New compounds and medical uses thereof |
| GB202304661D0 (en) | 2023-03-29 | 2023-05-10 | Atrogi Ab | New compounds and medical uses thereof |
| EP4688766A1 (en) | 2023-03-29 | 2026-02-11 | Atrogi AB | Heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
| GB202414472D0 (en) | 2024-10-02 | 2024-11-13 | Atrogi Ab | New compounds and uses thereof |
| GB202414491D0 (en) | 2024-10-02 | 2024-11-13 | Atrogi Ab | New compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE210031C (https=) | ||||
| NL288243A (https=) | 1962-01-29 | |||
| GB979389A (en) | 1962-01-29 | 1965-01-01 | Ici Ltd | Pharmaceutical compositions containing naphthalene derivatives |
| US3975391A (en) | 1973-12-26 | 1976-08-17 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
| US3952101A (en) | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| JPS596866B2 (ja) | 1975-05-22 | 1984-02-15 | オオツカセイヤク カブシキガイシヤ | ５−（（２− アルキルアミノ −１− ヒドロキシ ） アルキル ） カルボスチリルユウドウタイノセイゾウホウ |
| JPS52283A (en) | 1975-06-23 | 1977-01-05 | Otsuka Pharmaceut Co Ltd | Process for preparation of carbostyril derivatives |
| JPS5919540B2 (ja) | 1976-10-13 | 1984-05-07 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| US4082847A (en) | 1976-12-06 | 1978-04-04 | Merck & Co., Inc. | Substituted aminoethanols and pharmaceutical use |
| JPS5742673A (en) | 1980-08-29 | 1982-03-10 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| DE3115993A1 (de) | 1981-04-13 | 1982-11-11 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue indol-derivate, verfahren zu ihrer herstellung und pharmazeutische praeparate, die diese verbindungen enthalten |
| FR2528043A1 (fr) | 1982-06-03 | 1983-12-09 | Roussel Uclaf | Nouveaux derives de la 1,3-dihydro 4-/1-hydroxy-2-amino-ethyl/2h-indol-2-one, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| US4853381A (en) | 1984-04-17 | 1989-08-01 | Glaxo Group Limited | Ethanolamine compounds |
| US4600710A (en) * | 1985-03-14 | 1986-07-15 | G. D. Searle & Co. | β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives |
| EP0195397B1 (en) | 1985-03-21 | 1989-12-13 | American Cyanamid Company | M-cyanophenethanolamines as animal growth promoters and antilipogenic agents |
| US5019578A (en) | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| NZ226991A (en) | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| DE3800096A1 (de) | 1988-01-05 | 1989-07-13 | Bayer Ag | Verwendung von benzimidazolderivaten als leistungsfoerderer |
| DE3918834A1 (de) | 1989-01-26 | 1990-08-02 | Bayer Ag | Aryl- und heteroarylethanol-pyridylalkylamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren und als mittel gegen adipositas |
| DE3905028A1 (de) | 1989-02-18 | 1990-08-23 | Bayer Ag | 2,4-dihalogen-6-pyridylethanolphenylisopropylamine, verfahren zu ihrer herstellung und ihre verwendung zur verschiebung des protein-fett-verhaeltnisses zugunsten von protein |
| CA2087449A1 (en) | 1990-08-13 | 1992-02-14 | Joseph L. Roba | Use of heterocyclic amino-alcohol compounds for treatment of cns diseases |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| JP2001511555A (ja) * | 1997-07-25 | 2001-08-14 | ブリティッシュ・テレコミュニケーションズ・パブリック・リミテッド・カンパニー | ソフトウエアシステムの生成 |
| JPH1186867A (ja) | 1997-09-11 | 1999-03-30 | Ricoh Co Ltd | 電極および該電極を使用した電気化学素子 |
| GB2356197A (en) | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| AU2003251949A1 (en) | 2002-07-18 | 2004-02-09 | Vanderbilt University | Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype |
| WO2004087142A1 (en) | 2003-04-04 | 2004-10-14 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| EP1684764A2 (en) | 2003-10-09 | 2006-08-02 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| JP2006016314A (ja) | 2004-06-30 | 2006-01-19 | Sumitomo Chemical Co Ltd | 光学活性アミド化合物の製造方法 |
| US7528175B2 (en) | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| US8426475B2 (en) | 2005-04-13 | 2013-04-23 | Astion Development A/S | Treatment of connective tissue diseases of the skin |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| UY32622A (es) | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
| PL2657227T3 (pl) | 2010-12-22 | 2016-09-30 | Nowa podstawiona pochodna izochinoliny | |
| WO2012163942A1 (en) * | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| CN116898848A (zh) * | 2012-01-18 | 2023-10-20 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| CA2917159C (en) | 2013-07-08 | 2022-08-23 | Auspex Pharmaceuticals, Inc. | Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
| AU2016295604B2 (en) | 2015-07-23 | 2019-08-01 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| CN114340740A (zh) | 2019-07-01 | 2022-04-12 | 库拉森疗法公司 | β肾上腺素能激动剂及其使用方法 |
-
2020
- 2020-03-26 WO PCT/US2020/024948 patent/WO2020198466A1/en not_active Ceased
- 2020-03-26 AU AU2020248435A patent/AU2020248435B2/en active Active
- 2020-03-26 TW TW109110283A patent/TWI886121B/zh active
- 2020-03-26 MX MX2021011728A patent/MX2021011728A/es unknown
- 2020-03-26 CA CA3130291A patent/CA3130291A1/en active Pending
- 2020-03-26 EP EP20779258.1A patent/EP3946329A4/en active Pending
- 2020-03-26 IL IL285759A patent/IL285759B2/en unknown
- 2020-03-26 US US16/831,370 patent/US10947196B2/en active Active
- 2020-03-26 US US17/440,705 patent/US12448352B2/en active Active
- 2020-03-26 JP JP2021557367A patent/JP7682097B2/ja active Active
- 2020-03-26 US US16/831,285 patent/US11040944B2/en active Active
- 2020-03-26 BR BR112021018481A patent/BR112021018481A2/pt unknown
- 2020-03-26 CN CN202080023519.5A patent/CN114007615A/zh active Pending
- 2020-03-26 KR KR1020217030777A patent/KR102948270B1/ko active Active
-
2021
- 2021-06-22 US US17/355,063 patent/US20210371380A1/en not_active Abandoned
- 2021-09-08 ZA ZA2021/06625A patent/ZA202106625B/en unknown
-
2025
- 2025-02-26 JP JP2025028466A patent/JP2025087743A/ja active Pending
- 2025-09-24 US US19/339,240 patent/US20260109671A1/en active Pending